The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to
asymptomatic (no symptoms) HIV-infected patients.
Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the
protein integrase to infect a cell. Integrase inhibitors block integrase and may stop
replication of HIV.
Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. The HIV-1 virus
uses the protein integrase to incorporate its genetic material into the infected host cell.
Integrase inhibitors block integrase and may stop replication of the HIV-1 virus.
In this open-label, Phase I/II study, 3 groups of HIV-positive patients (12 patients total)
receive escalating doses of intravenous zintevir for 14 consecutive days.
You may be eligible for this study if you:
- Are HIV-positive, but do not have any symptoms of HIV infection.
- Have a CD4 count greater than 200 cells/mm3.
- Have a viral load (level of HIV in the body) greater than 4,000 copies/ml.
- Are at least 18 years old.
You will not be eligible for this study if you:
- Tend to have abnormal bleeding or other blood problems.
- Have an active AIDS-defining illness.
- Have a history of serious disease or illness.
- Abuse alcohol or drugs.
- Have received certain medications.